Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.38 |
| ▸ | LSS | P48449 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 2/20 | 0.37 |
| ▸ | NOS2 | P35228 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847338 | 0.96 | CYP1A2 (0.61) | CYP1A2LMNAMAPK1HTTTSHR | |
| SCHEMBL4836059 | 0.91 | CYP1A2 (0.67) | CYP1A2LMNAMAPK1HTTTSHR | |
| SCHEMBL14724955 | 0.91 | CYP1A2 (0.58) | CYP1A2LMNAMAPK1HTTMAPT | |
| SCHEMBL2449584 | 0.91 | CYP1A2 (0.58) | CYP1A2LMNAMAPK1HTTMAPT | |
| SCHEMBL42810 | 0.91 | CYP1A2 (0.58) | CYP1A2LMNAMAPK1HTTMAPT | |
| SCHEMBL4843036 | 0.87 | CYP1A2 (0.48) | CYP1A2LMNAMAPK1HTTTSHR | |
| SCHEMBL8914908 | 0.85 | CYP1A2 (0.52) | CYP1A2LMNAMAPK1HTTMAPT | |
| SCHEMBL6746516 | 0.85 | CYP1A2 (0.52) | CYP1A2LMNAMAPK1HTTMAPT | |
| SCHEMBL6748553 | 0.85 | CYP1A2 (0.52) | CYP1A2LMNAMAPK1HTTMAPT | |
| SCHEMBL8914904 | 0.85 | CYP1A2 (0.52) | CYP1A2LMNAMAPK1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1710223-B1 | PROCESS FOR PRODUCING ALDEHYDE COMPOUND OR KETONE COMPOUND WITH USE OF MICROREACTOR | UBE INDUSTRIES (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-7332632-B2 | Method for producing aldehyde compound or ketone compound by using microreactor | Ubē Industries, Ltd. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-20070149823-A1 | Method for producing aldehyde compound or ketone compound by using microreactor | UBE INDUSTRIES, LTD., A CORPORATION OF JAPAN (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1710223-A1 | PROCESS FOR PRODUCING ALDEHYDE COMPOUND OR KETONE COMPOUND WITH USE OF MICROREACTOR | Ube Industries, Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149823-A1 | Method for producing aldehyde compound or ketone compound by using microreactor | ADH1C, ADH1A, ALDH1A1 | CYP1A2 1008/4885LMNA 3809/4885MAPK1 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.